Search
GAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreFirst Horizon 2020 Work Programme update – budget, and launch of FTI and innovation prizes
Click here for the PDF.
Read morePractical information
When do the meetings take place?The Spring Course will take place from 07-14 March 2025 in France. The first follow-up meeting will take place during the EHA2025 Congress from 12 – 15 June 2025.
Read moreAdolescents and young adults (AYA)
Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.
Read moreEHA Mentorship Program overview
Program goalsThe EHA Mentorship Program aims to:
Provide the early and mid-career European hematology community with access to mentorship that's relevant to their career stage
Expose hematologists and researchers from less professionally mobile backgrounds to career mentorship and best practices from other…
Junior membership
If you're at an early stage in your career, junior membership can be a great way to:
Expand your knowledge
Make connections
Access EHA's early career opportunities
Stay up to date with the latest developments
As a junior member, you can also apply for EHA…
Emeritus membership
If you're a scientific researcher, physician, or healthcare-affiliated professional who's now retired or is close to retirement, you can join EHA at a reduced rate.
Read morePosition of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
Revision of the EU’s pharmaceutical legislation
Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- »